Tetradecylthioacetic Acid for Health & Longevity - Quick Reference Sheet

Tetradecylthioacetic Acid for Health & Longevity

Created on 09/29/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

Tetradecylthioacetic acid is a laboratory-made fatty acid, sold as a supplement and studied for its effects on blood fats. Its most credible benefit is short-term blood-fat improvement in selected clinical settings. Weight loss, better glucose control, fewer heart attacks, and longer life are not established. Short exposures were generally tolerated but say little about long-term harms; most research comes from one closely connected group with disclosed commercial interests. (Full Review)

Protocol

Research doses
200, 600, or 1,000 mg orally once daily
For seven days in healthy volunteers; parallel dose groups, not a demonstrated individual escalation schedule
Four-week regimen
1,000 mg in capsules once daily
For 28 days; lipids, glucose, and safety blood parameters measured at baseline, day 14, and day 28
Alternative schedule
1 g/day split with meals
Described by Examine; no head-to-head trial shows an advantage over once-daily dosing
Time to effect
Improved blood-lipid profile
Over four weeks
Human lipid signals in 28-day disease studies
Healthy volunteers
Seven days
Lipid change not established

Benefits

Contraindications
  • Pregnancy, breastfeeding, and children under 18
  • Known allergy to tetradecylthioacetic acid or formulation ingredients
  • Significant active heart, liver, or kidney disease outside a monitored research setting
Key Interactions
  • Lipid-lowering medicines: statins (atorvastatin, rosuvastatin), fibrates (fenofibrate, gemfibrozil)
  • Diabetes medicines: insulin, sulfonylureas (gliclazide, glimepiride)
  • Blood-pressure medicines (amlodipine, losartan)
  • Antiretrovirals: protease inhibitors (ritonavir, lopinavir)
  • Antipsychotics (olanzapine, clozapine)
  • Anticoagulants (warfarin, apixaban) and nonprescription medicines (aspirin, ibuprofen, paracetamol)
  • Fish oil
  • Other lipid supplements: niacin, red yeast rice
  • Weight-loss combinations: oleoylethanolamide

Risk & Side Effects

  • High:
  • Medium:
  • Low: Mild adverse events during short-term exposure
  • Speculative: Impaired cardiac energy efficiency; Liver-fat accumulation and metabolic remodeling; Altered essential-fat balance; Adverse vascular response to local delivery; Altered vitamin-related metabolism

Monitoring

Marker Target Why
Fasting lipid profile LDL below 100 mg/dL (2.6 mmol/L); triglycerides below 100 mg/dL (1.1 mmol/L); HDL above 50 mg/dL (1.3 mmol/L) Measure intended response
Fasting glucose 75–90 mg/dL (4.2–5.0 mmol/L) Detect metabolic change
Liver enzymes and bilirubin ALT and AST about 10–25 U/L; bilirubin 0.3–1.0 mg/dL (5–17 µmol/L) Detect possible liver injury
Creatinine and estimated filtration rate Estimated filtration rate above 90 mL/min/1.73 m²; creatinine about 0.7–1.1 mg/dL, varying with muscle mass Detect kidney change
Sodium, potassium, magnesium Sodium 138–142 mmol/L; potassium 4.0–4.8 mmol/L; serum magnesium 2.0–2.4 mg/dL (0.82–0.99 mmol/L) Evaluate cramps or weakness
Complete blood count Hemoglobin 13.5–15.5 g/dL (men) or 12.5–14.5 g/dL (women); platelets 175–250 ×10⁹/L Identify blood-cell changes
Blood pressure and resting pulse Below 120/80 mmHg; resting pulse 55–70 beats per minute Detect circulation changes
Plasma fatty-acid profile, if available Omega-3 index 8–12% when measured Characterize omega-3 shifts

Cadence: Baseline; day 14 and day 28 (mirrors the registered diabetes study); two to four weeks after cessation (extrapolation); earlier if symptoms occur. No target ranges specific to tetradecylthioacetic acid are validated; changes from baseline provide context.

Qualitative Assessment

  • Physical capacity: Exercise tolerance, breathlessness, muscle symptoms, and recovery.
  • General tolerance: Digestive symptoms, dizziness, swelling, and new skin reactions.
  • Daily function: Sleep, energy, and cognitive clarity; improvement alone cannot establish disease prevention.